A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults

Condition:   Influenza Interventions:   Biological: DCVC H1 HA mRNA vaccine;   Biological: Quadrivalent Recombinant Seasonal Influenza Vaccine;   Other: Sodium Chloride, 0.9% Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials